Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E33.83 EPS (ttm)7.40 Insider Own1.59% Shs Outstand97.97M Perf Week-6.24%
Market Cap24.52B Forward P/E41.58 EPS next Y6.02 Insider Trans-26.44% Shs Float78.49M Perf Month15.48%
Income837.49M PEG1.07 EPS next Q0.96 Inst Own78.15% Short Float4.87% Perf Quarter57.06%
Sales1.59B P/S15.46 EPS this Y376.00% Inst Trans0.10% Short Ratio3.45 Perf Half Y43.40%
Book/sh14.39 P/B17.39 EPS next Y53.96% ROA46.19% Target Price287.24 Perf Year98.55%
Cash/sh3.14 P/C79.69 EPS next 5Y31.57% ROE87.68% 52W Range107.31 - 283.99 Perf YTD46.32%
Dividend- P/FCF625.74 EPS past 5Y0.00% ROI51.25% 52W High-11.86% Beta1.04
Dividend %- Quick Ratio6.44 Sales past 5Y61.61% Gross Margin93.62% 52W Low133.26% ATR10.56
Employees1950 Current Ratio6.63 Sales Q/Q89.68% Oper. Margin37.10% RSI (14)54.03 Volatility4.60% 4.29%
OptionableYes Debt/Eq0.33 EPS Q/Q735.91% Profit Margin52.79% Rel Volume0.61 Prev Close254.87
ShortableYes LT Debt/Eq0.33 EarningsMay 03 BMO Payout0.00% Avg Volume1.11M Price250.31
Recom2.10 SMA20-2.48% SMA5015.22% SMA20042.93% Volume676,349 Change-1.79%
17-May-13Initiated UBS Neutral $290
06-May-13Reiterated RBC Capital Mkts Outperform $270 → $286
06-May-13Reiterated Barclays Overweight $275 → $305
02-May-13Reiterated Barclays Overweight $194 → $275
28-Feb-13Initiated Barclays Overweight $194
21-Dec-12Reiterated RBC Capital Mkts Outperform $171 → $190
14-Feb-12Reiterated RBC Capital Mkts Outperform $83 → $130
10-Jan-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
05-Dec-11Reiterated Brean Murray Buy $78 → $67
28-Jul-11Upgrade RBC Capital Mkts Sector Perform → Outperform $70 → $70
09-May-11Reiterated Needham Buy $49 → $60
29-Apr-11Reiterated Barclays Capital Overweight $64 → $72
29-Apr-11Downgrade RBC Capital Mkts Outperform → Sector Perform $70 → $70
28-Apr-11Reiterated RBC Capital Mkts Outperform $48 → $70
28-Apr-11Reiterated Brean Murray Buy $67 → $78
27-Apr-11Reiterated Brean Murray Buy $57 → $67
27-Apr-11Reiterated Barclays Capital Overweight $61 → $64
27-Apr-11Initiated Boenning & Scattergood Outperform $58
18-Apr-11Reiterated Brean Murray Buy $46 → $57
13-Apr-11Reiterated Barclays Capital Overweight $47 → $56
23-May-13 07:06PM  Todays 3 Worst Stocks at Motley Fool
05:01PM  Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard at TheStreet
02:04PM  Agree To Buy Regeneron Pharmaceuticals At $165, Earn 9.8% at Forbes
02:04PM  Amgen Stock Checkup for May at Motley Fool
09:01AM  Applied Materials CEO Sells 300K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
22-May-13 05:22PM  Is This Momentum Stocks Rally Over? at Motley Fool
04:00PM  Sanofi/REGN's Dupilumab Data Published Zacks
03:56PM  Regeneron Shareholders Watching Optina Trial Closely at Seeking Alpha
03:20PM  Regeneron moves higher on asthma drug study data AP
02:06PM  Wednesdays movers: Saks rallies for third day at MarketWatch
12:09PM  Stocks Stage Broad Advance; Bristol-Myers Leads Medicals at Investor's Business Daily
11:51AM  Wednesdays movers: Drug makers lead S&P 500 at MarketWatch
08:05AM  Check Out 5 Big Caps With Long-Term Growth Prospects at Investor's Business Daily
21-May-13 06:32PM  Regeneron and Sanofi: An Unstoppable Biotech Duo? at Motley Fool
04:12PM  New Drug May Help Some Asthmatics, Study Finds at New York Times
08:52AM  New Asthma Drug Generates Excitement For Patients -- And Its Maker at Forbes
08:15AM  InPlay: Regeneron Pharms and Sanofi and announce publication of positive Phase 2a results of dupilumab in asthma in the New England Journal of Medicine Briefing.com
08:15AM  Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine PR Newswire
08:14AM  Regeneron, Sanofi asthma drug seen as potential game changer at Reuters
20-May-13 07:01PM  On The Fly: After Hours Movers at theflyonthewall.com
06:26PM  Regeneron settles all pending litigation with Roche's Genentech at Reuters
01:50PM  Regeneron Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 10:00 AM at Seeking Alpha
01:04PM  5 Stocks Underperforming Today In The Drugs Industry at TheStreet
10:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
10:01AM  Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) at TheStreet
09:51AM  2 Healthcare Companies And 1 Consumer Goods Company With Recent Intensive Insider Selling at Seeking Alpha
18-May-13 02:30PM  Will ASCO Unlock Big Value in This Cancer Drug Class? at Motley Fool
17-May-13 06:51PM  IBD 50 Stocks Delivering Strong Earnings, Sales Gains at Investor's Business Daily
03:21AM  Coverage initiated on Regeneron Pharms by UBS Briefing.com
16-May-13 03:38PM  A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street Transcript Wall Street Transcript
09:49AM  Pepper Snapple Group CEO Sells More Than 67K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
09:19AM  S&P 500 Stocks Farthest Above 50-DMAs at Seeking Alpha
08:28AM  Sanofi and Regeneron's Latest Partnership at Motley Fool
07:51AM  The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals Zacks
15-May-13 05:19PM  4 Healthcare Stock Stories Prescribed for Investors at Wall St. Cheat Sheet
05:01PM  Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard at TheStreet
05:00PM  Sanofi/REGN Commence Enrollment Zacks
01:03PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
12:49PM  Cramer: Buy Aqua America, Radian, Regeneron, and These 2 Stocks at Wall St. Cheat Sheet
09:31AM  [video] Cramer's '4 Horsemen of the Apocalypse' for Shorts at CNBC
01:31AM  Sanofi recruits patients for arthritis trials at Reuters
01:00AM  Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA) PR Newswire
14-May-13 06:00PM  Jim Cramer's 5 Investing Sweet Spots at CNBC
04:25PM  Why This Stock's Crash is a Buying Opportunity at Motley Fool
09:52AM  [video] Cramer's Six in 60: Monster Beverage, Clorox & More at CNBC
06:10AM  [$$] Biotech Fund: Many Healthy Returns at Barrons.com
13-May-13 11:24AM  Is Regeneron A Value Pick In The Pharma Sector? at Seeking Alpha
08:58AM  NorthStar Realty COO Sells More Than 192K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
11-May-13 11:31AM  The 4 Stocks Driving the S&P 500 Higher at Motley Fool
10-May-13 04:39PM  Cramer: Biotech Makes a Comeback at TheStreet
01:04PM  REGENERON PHARMACEUTICALS INC Financials EDGAR Online Financials
12:52PM  Biotech Makes a Comeback TheStreet
11:14AM  Regeneron Stock Hits New 52-Week High (REGN) at TheStreet
08:58AM  Comcast Executive VP Sells More Than 23K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
09-May-13 10:28AM  Nailing Big Winners In The Market at Seeking Alpha
09:25AM  Bed Bath & Beyond CFO Sells 125K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
06:00AM  Biotech Is Where the Bucks Are TheStreet
08-May-13 01:22PM  Double-Digit Returns from the Biotechnology Strategy at Motley Fool
10:00AM  Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) at TheStreet
09:30AM  Regeneron Announces Upcoming 2013 Investor Conference Presentations PR Newswire
09:05AM  Regeneron Leads Top 5 Big Cap Stocks By Sales Growth at Investor's Business Daily
07-May-13 10:26AM  Regeneron: Solid Q1 Creates Platform For Further Upside at Seeking Alpha
07:41AM  [$$] Regeneron Set for Eye-Opening Upside at Barrons.com
06-May-13 09:34PM  3 Healthcare Stock Stories For Monday Investment Wellness at Wall St. Cheat Sheet
05:46PM  How Regeneron's Eylea Became A 'Trump Card' In The Niche AMD Market at Seeking Alpha
01:04PM  5 Stocks Dragging In The Health Care Sector at TheStreet
09:46AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online
04-May-13 03:46PM  5 Healthcare Stocks Heading in Different Directions After Earnings at Wall St. Cheat Sheet
03:22PM  Who Got Rich This Week: Pharma Legend P. Roy Vagelos, Chief Yelper Levchin And More at Forbes
11:30AM  3 Booming Biotech Companies at Motley Fool
07:00AM  The Best- And Worst-Performing Biotech Stocks, April 26 to May 3 at Forbes
03-May-13 06:58PM  [video] No Huddle Offense: What's Working In Pharma at CNBC +7.05%
06:04PM  Regeneron Pharma raises sales forecast for Eylea AP
05:25PM  Regeneron Earnings Soar As Eylea Sales Skyrocket Investor's Business Daily
05:00PM  Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Winner at TheStreet
04:33PM  On The Fly: Closing Wrap at theflyonthewall.com
04:18PM  Fridays movers: Regeneron, LinkedIn at MarketWatch
02:10PM  Regeneron Eyes 2 New Ophthalmology Treatments at Motley Fool
01:55PM  Eylea Drives Earnings at Regeneron Zacks
12:20PM  Regeneron Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
01-May-13 08:30PM  Why Allergan's Pain Is Regeneron's Gain at Motley Fool +10.30%
06:08PM  Nasdaq stocks posting largest percentage increases AP
06:00PM  [video] Cramer's Thoughts on Wednesday's Decline at CNBC
05:26PM  After the close: Allergan losses worsen, Humana gains on earnings at MarketWatch
05:01PM  On The Fly: Closing Wrap at theflyonthewall.com
04:29PM  Forbes Earnings Preview: Regeneron Pharmaceuticals at Forbes
04:11PM  Stocks Pull Back In Higher Turnover, But Regeneron Soars at Investor's Business Daily
04:00PM  [video] Tough Day for Stocks at CNBC
03:58PM  Regeneron Soars To New High On Allergan's Test Delays at Investor's Business Daily
03:39PM  Allergan slides, Regeneron surges on eye drug news AP
02:51PM  Allergan shares fall on delay of eye drug study AP
01:18PM  Nasdaq stocks posting largest percentage increases AP
01:12PM  On The Fly: Midday Wrap at theflyonthewall.com
11:51AM  Allergan falls, Regeneron jumps on speculation over vision-loss drug at MarketWatch
11:48AM  Regeneron surges after Allergan says vision-loss drug delayed at theflyonthewall.com
11:46AM  Analyst Moves: ECL, ESRX, REGN at Forbes
11:17AM  BRIEF-Regeneron Pharma shares resume trading, up 16 percent at Reuters
11:16AM  BRIEF-Allergan resumes trading down 11.5 percent after company says phase 2 eye drug data does not support directly moving to phase 3 at Reuters
11:11AM  Allergan falls, Regeneron jumps after Allergan comments on drug trial at theflyonthewall.com
11:11AM  BRIEF-Regeneron Pharma shares halted, last up 14.3 pct at Reuters
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 21Option Exercise19.494,02378,396125,389May 22 05:12 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 21Sale259.7466,83517,359,65258,554May 22 05:12 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 20Option Exercise20.02147,9672,962,169135,803May 22 05:12 PM
BROWN MICHAEL SDirectorMay 17Sale269.025,0001,345,12014,662May 17 02:37 PM
BROWN MICHAEL SDirectorMay 15Option Exercise24.4115,000366,15029,662May 17 02:37 PM
BROWN MICHAEL SDirectorMay 15Sale278.2810,0002,782,80019,662May 17 02:37 PM
Aberman Michael SVP Strategy and Investor RelatMay 14Sale279.615,5291,545,96011,700May 15 05:04 PM
Aberman Michael SVP Strategy and Investor RelatMay 13Option Exercise24.0012,500300,00024,200May 15 05:04 PM
STAHL NEILSVP Research and Development SMay 13Sale276.8823,0386,378,80648,988May 14 11:51 AM
SING GEORGE LDirectorMay 10Option Exercise15.015,00075,050117,772May 10 04:19 PM
STAHL NEILSVP Research and Development SMay 10Option Exercise21.9255,4381,215,201104,426May 14 11:51 AM
SING GEORGE LDirectorMay 10Sale270.005,0001,350,000112,772May 10 04:19 PM
Terifay Robert JSVP CommercialMay 08Sale261.238,2312,150,19215,324May 09 04:59 PM
Terifay Robert JSVP CommercialMay 07Option Exercise16.8016,923284,30630,074May 09 04:59 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriMay 07Sale262.64100,00026,263,5811,106,395May 08 05:49 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 07Sale261.6113,7253,590,63710,736May 08 05:51 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriMay 06Option Exercise13.00192,3082,500,0041,309,638May 08 05:49 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise53.2313,334709,8348,334May 08 05:52 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 06Option Exercise16.8032,950553,56039,784May 08 05:51 PM
SHOOTER ERIC MDirectorMay 06Option Exercise37.0920,000741,8005,039May 08 05:53 PM
GILMAN ALFRED GDirectorMay 06Option Exercise21.7730,000652,9509,600May 08 05:54 PM
Aberman Michael SVP Strategy and Investor RelatMay 06Option Exercise24.008,334200,01618,434May 08 05:55 PM
VAGELOS P ROYChairman of the BoardMay 06Sale263.2113,4823,548,550114,018May 08 05:50 PM
Tessier-Lavigne MarcDirectorMay 06Sale260.9113,3343,478,9420May 08 05:52 PM
SHOOTER ERIC MDirectorMay 06Sale259.3620,0005,187,2240May 08 05:53 PM
SHOOTER ERIC MDirectorMay 06Sale261.9610,0002,619,6482,500May 08 05:53 PM
GILMAN ALFRED GDirectorMay 06Sale261.0430,0007,831,3020May 08 05:54 PM
Aberman Michael SVP Strategy and Investor RelatMay 06Sale257.138,3342,142,92711,700May 08 05:55 PM
McCorkle Douglas SVP Controller & Asst TreasurerMay 02Sale244.792,213541,7254,000May 03 04:09 PM
McCorkle Douglas SVP Controller & Asst TreasurerMay 01Option Exercise52.035,875305,6769,875May 03 04:09 PM
SCHLEIFER LEONARD SPresident & CEOMay 01Sale237.65100,00023,765,28942,087May 03 04:09 PM
McCorkle Douglas SVP Controller and Asst TreasurApr 12Sale211.013,129660,2354,000Apr 16 12:39 PM
McCorkle Douglas SVP Controller and Asst TreasurApr 11Option Exercise30.635,875179,9519,875Apr 16 12:39 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise24.415,000122,0505,000Apr 02 09:23 AM
GOLDSTEIN JOSEPH LDirectorApr 01Sale180.005,000900,0000Apr 02 09:23 AM
BROWN MICHAEL SDirectorMar 21Option Exercise18.6115,000279,15021,422Mar 22 04:32 PM
BROWN MICHAEL SDirectorMar 21Sale173.2715,0002,599,02214,662Mar 22 04:32 PM
SCHLEIFER LEONARD SPresident & CEOMar 19Sale175.023,655639,698142,087Mar 21 04:18 PM
SCHLEIFER LEONARD SPresident & CEOMar 13Sale175.014,662815,897145,742Mar 15 05:03 PM
SCHLEIFER LEONARD SPresident & CEOMar 07Sale175.133,534618,909150,404Mar 07 05:08 PM
SCHLEIFER LEONARD SPresident & CEOMar 06Sale175.3869,00312,101,570153,938Mar 07 05:08 PM
SCHLEIFER LEONARD SPresident & CEOMar 05Sale175.2119,1463,354,571222,941Mar 07 05:08 PM
SHOOTER ERIC MDirectorFeb 26Sale160.0010,0001,600,0002,500Feb 28 02:32 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaJan 16Sale172.167,8781,356,27258,592Jan 17 04:30 PM
GOLDSTEIN JOSEPH LDirectorJan 09Option Exercise57.115,000285,5505,000Jan 09 05:13 PM
Powchik PeterSVP Clin Devel & Reg AffairsJan 09Option Exercise17.385,75299,98020,742Jan 10 09:25 AM
GOLDSTEIN JOSEPH LDirectorJan 09Sale185.005,000925,0000Jan 09 05:13 PM
GOLDSTEIN JOSEPH LDirectorJan 04Option Exercise33.425,000167,1002,740Jan 07 10:02 AM
GOLDSTEIN JOSEPH LDirectorJan 04Sale180.835,000904,1270Jan 07 10:02 AM
Powchik PeterSVP Clin Devel & Reg AffairsJan 03Sale182.1113,5862,474,09114,990Jan 04 10:00 AM
Powchik PeterSVP Clin Devel & Reg AffairsJan 02Option Exercise21.2530,000637,50044,990Jan 04 10:00 AM
Van Plew Daniel PSVP & Gen Mgr IOPSDec 20Option Exercise16.802,05034,4406,834Dec 21 03:17 PM
Powchik PeterSVP Clin Devel & Reg AffairsDec 20Sale170.646,6231,130,16414,990Dec 20 04:17 PM
YANCOPOULOS GEORGEEVP CSO Pres Regen Res LabsDec 19Option Exercise13.7750,846699,9781,117,330Dec 21 03:11 PM
Powchik PeterSVP Clin Devel & Reg AffairsDec 19Sale178.5010,3561,848,53621,613Dec 20 04:17 PM
McCorkle Douglas SVP Controller & Asst TreasurerDec 19Sale175.441,841322,9864,000Dec 20 04:16 PM
McCorkle Douglas SVP Controller & Asst TreasurerDec 18Option Exercise21.254,62598,2817,873Dec 20 04:16 PM
Aberman Michael SVP Strategy and Investor RelatDec 18Option Exercise24.001,20028,80011,700Dec 19 04:24 PM
Terifay Robert JSVP CommercialDec 18Option Exercise16.805,95299,99415,324Dec 19 04:23 PM
Powchik PeterSVP Clin Devel & Reg AffairsDec 18Option Exercise31.6138,2481,209,09039,446Dec 20 04:17 PM
McCorkle Douglas SVP Controller & Asst TreasurerDec 18Sale179.00752134,6065,841Dec 20 04:16 PM
McCorkle Douglas SVP Controller & Asst TreasurerDec 17Option Exercise16.805,00084,0004,800Dec 18 11:31 AM
STAHL NEILSVP Res and Devel SciencesDec 17Option Exercise16.805,95299,99448,988Dec 18 11:31 AM
GOLDBERG MURRAY ASVP Fin & Admin CFO Asst SecyDec 17Option Exercise20.321,85037,59266,470Dec 18 11:34 AM
YANCOPOULOS GEORGEEVP CSO Pres Regen Res LabsDec 17Option Exercise109.2910,3691,133,2281,304,811Dec 18 11:33 AM
McCorkle Douglas SVP Controller & Asst TreasurerDec 17Sale179.201,000179,1984,000Dec 18 11:31 AM
Aberman Michael SVP Strategy and Investor RelatDec 11Sale185.063,368623,26810,500Dec 12 09:34 AM
Aberman Michael SVP Strategy and Investor RelatDec 10Option Exercise30.637,500229,72518,000Dec 12 09:34 AM
STAHL NEILSVP Res and Devel SciencesNov 30Option Exercise21.099,483199,99451,422Dec 03 04:20 PM
ROBERTS WILLIAMVP Regulat Dev & Med SafetyNov 30Sale180.7811,5002,078,9750Dec 04 04:09 PM
Aberman Michael SVP Strategy and Investor RelatNov 30Sale180.643,904705,22810,500Dec 03 04:21 PM
STAHL NEILSVP Res and Devel SciencesNov 30Sale181.0117,1823,110,11441,939Dec 03 04:20 PM
Aberman Michael SVP Strategy and Investor RelatNov 29Option Exercise24.008,334200,01618,834Dec 03 04:21 PM
VAGELOS P ROYChairman of the BoardNov 29Sale179.4778,63014,111,46856,946Nov 30 01:47 PM
SING GEORGE LDirectorNov 29Sale185.005,000925,000122,772Nov 29 01:30 PM
VAGELOS P ROYChairman of the BoardNov 28Sale175.037,0041,225,910135,576Nov 30 01:47 PM
VAGELOS P ROYChairman of the BoardNov 27Sale175.3036,2466,353,788142,580Nov 27 06:23 PM
BAKER CHARLES ADirectorNov 26Option Exercise9.1715,000137,55016,155Nov 27 05:54 PM
VAGELOS P ROYChairman of the BoardNov 26Sale175.1228,5074,992,146178,826Nov 27 06:23 PM
BAKER CHARLES ADirectorNov 26Sale173.8715,0002,607,9869,590Nov 27 05:54 PM
VAGELOS P ROYChairman of the BoardNov 23Option Exercise19.43312,5006,071,875369,446Nov 27 06:23 PM
Terifay Robert JSVP CommercialNov 23Sale174.459,7451,699,9709,372Nov 26 03:39 PM
Terifay Robert JSVP CommercialNov 21Option Exercise16.8020,000336,00029,372Nov 26 03:39 PM
STAHL NEILSVP Res and Devel SciencesNov 21Sale174.3024,3574,245,44259,121Nov 21 03:50 PM
STAHL NEILSVP Res and Devel SciencesNov 20Option Exercise16.8054,500915,600104,219Nov 21 03:50 PM
VAGELOS P ROYChairman of the BoardNov 19Sale160.6132,5005,219,974127,500Nov 20 09:50 AM
SCHLEIFER LEONARD SPresident & CEONov 16Option Exercise111.0143,7574,857,465338,920Nov 19 05:25 PM
SING GEORGE LDirectorNov 16Sale152.005,000760,000127,772Nov 20 04:14 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 16Sale155.7018,7412,917,8994,784Nov 16 05:03 PM
BROWN MICHAEL SDirectorNov 14Option Exercise23.847,000166,88021,662Nov 15 10:26 AM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaNov 14Sale148.273,156467,95483,977Nov 15 05:12 PM
BROWN MICHAEL SDirectorNov 14Sale147.037,0001,029,21014,662Nov 15 10:26 AM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaNov 13Option Exercise41.738,176341,19595,357Nov 15 05:12 PM
SING GEORGE LDirectorNov 13Sale148.005,000740,000132,772Nov 15 05:13 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaNov 13Sale147.266,537962,63487,133Nov 15 05:12 PM
Powchik PeterSVP Clinical Development & RegNov 08Sale138.6215,1442,099,22114,990Nov 09 10:27 AM
RYAN ARTHUR FDirectorNov 01Sale145.5710,0001,455,70040,355Nov 05 10:14 AM
BROWN MICHAEL SDirectorOct 26Option Exercise23.843,00071,52017,662Oct 26 03:43 PM
BROWN MICHAEL SDirectorOct 26Sale154.693,000464,07014,662Oct 26 03:43 PM
BROWN MICHAEL SDirectorOct 25Option Exercise23.842,00047,68016,662Oct 26 03:43 PM
open in yahoo | open in reuters | open in google